Searching for Innovation: The Top Deals in 2026

What were the key partnering deals made by the bio/pharmaceutical majors thus far in 2026? Which molecules and drug classes drove deal-making? DCAT Value Chain Insights takes an inside look.

What were the key partnering deals made by the bio/pharmaceutical majors thus far in 2026? Which molecules and drug classes drove deal-making? DCAT Value Chain Insights takes an inside look.

By Patricia Van Arnum, Editorial Director, DCAT, [email protected]

Partnering deals with China-based innovators
One of the themes in partnering deals among the bio/pharmaceutical majors in 2026 was an increase in cross-border licensing activity, particularly involving China-based innovator companies, with much of the deal-making focused on oncology, immunology, and metabolic disease assets. Highlights of the key deals announced this year (pending or closed) are outlined below.

AbbVie. AbbVie and RemeGen (Yantei, China) formed an agreement for the development, manufacturing and commercialization of RC148, an investigational programmed cell death-1 (PD-1)/vascular endothelial growth factor (VEGF)-targeted bispecific antibody, in a deal worth up to $5.6 billion ($650 million upfront and $4.95 billion in milestone payments). RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors. RC148 further strengthens AbbVie’s oncology portfolio by potentially offering new opportunities to explore combination regimens with AbbVie’s antibody drug conjugates (ADCs) such as investigational telisotuzumab adizutecan across multiple solid tumors, including non-small cell lung cancer and colorectal cancer.

AstraZeneca. AstraZeneca formed an agreement with CSPC Pharmaceuticals (Hong Kong) in a deal worth up to $18.5 billion ($1.2 billion upfront, $3.5 billion in research and development milestones, and $13.8 billion in sales milestones) for eight programs in obesity and Type 2 diabetes. The companies will initially progress four programs, which use CSPC’s AI peptide drug-discovery platform and its proprietary LiquidGel once-monthly dosing platform technology.

AstraZeneca and Sino Biopharmaceutical (Hong Kong) entered into an exclusive license agreement for the development, manufacturing, and commercialization of Sino Biopharmaceutical’s PDE3/4 inhibitor, TQC3721, a respiratory drug, in a deal worth up to $2.1 billion ($200 million upfront and $1.9 billion in milestone payments). Under the agreement, Sino Biopharmaceutical, grants AstraZeneca an exclusive license to develop, manufacture, and commercialize TQC3721 outside China. AstraZeneca also gains exclusive global rights for certain future development programs. Sino Biopharmaceutical is eligible to receive an upfront payment of $200 million, with additional development, regulatory, and sales milestones, totaling up to $1.9 billion, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 product

In addition, AstraZeneca completed its license agreement with Dizal Pharmaceutical (Shanghai) for Zegfrovy (sunvozertinib), an oral drug for treating non-small cell lung cancer, in a deal worth up to $1.5 billion ($600 million upfront and $900 million in milestone payments). Zegfrovy is approved in the US and China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.

Boehringer Ingelheim. Boehringer Ingelheim (BI) and Sino Biopharmaceutical (Hong Kong) and its subsidiaries (collectively, SBP Group) formed a multi-program option and license agreement for ADC and T-cell engagers technologies for treating cancer, in a deal worth up to $7.4 billion ($385 million upfront and up to $7 billion in option-exercise and milestone payments). The collaboration covers six biologic preclinical programs. Five programs center on LaNova Medicines (Shanghai) Co., Ltd, a wholly owned SBP Group subsidiary. The remaining program comes from Beijing Tide Pharmaceutical Co., Ltd., another SBP Group subsidiary.

Under the agreement, SBP Group will undertake early development. After agreed clinical milestones are reached, BI may exercise options for exclusive development, manufacturing, and commercialization rights outside mainland China, Hong Kong, and Macau for four programs, and worldwide rights for the remaining two programs.

Bristol-Myers Squibb. In May (May 2026), Bristol Myers Squibb (BMS) and Hengrui Pharma (Lianyungang and Shanghai, China) entered into global strategic collaboration and license agreements to advance a portfolio of 13 early-stage programs in oncology, hematology, and immunology, in a deal worth up to $15.2 billion ($600 million upfront and $14.6 billion in milestone payments). The agreements include four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five innovative assets to be jointly developed across several innovative modalities. Hengrui has the option to co-develop select assets and the potential to conduct certain commercialization activities globally with BMS.

Eli Lilly and Company. Lilly and Innovent Biologics (Suzhou, China) formed a pact to advance medicines in oncology and immunology in a deal worth up to $8.8 billion ($350 million upfront and $8.5 billion in milestone payments). Innovent will lead the development of programs from concept through clinical proof-of-concept (Phase II clinical trial completion) in China. The agreement grants Lilly an exclusive license to develop and commercialize the programs worldwide outside Greater China while Innovent retains rights in Greater China.

Lilly also announced in 2026 a licensing and research collaboration with Haisco Pharmaceutical Group (Beijing) to develop innovative medicines across multiple therapeutic areas, in a deal worth up to $3 billion ($87 million upfront and $2.9 billion in milestone payments). Haisco will be responsible for the discovery and identification of up to five innovative target programs while Lilly will lead investigational new drug (IND)-enabling studies, clinical development, and commercialization.

Lilly also partnered with Insilico Medicine (Hong Kong and Boston) in a $2.75-billion drug-discovery and development collaboration ($115 million upfront payment plus milestones payments and tiered royalties on future sales). The deal grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialization of oral therapeutics, now in preclinical development for multiple indications, discovered with Insilico’s AI-based drug-discovery engine. The companies had previously signed a $100-million pact last November (November 2025).

Lilly also partnered with Metis TechBio (Hong Kong) in a pact focused on the research and discovery of lipid nanoparticle (LNP)-based delivery to enable tissue-specific delivery of therapeutic modalities, in a deal worth up to $1.1 billion. Under the deal, Metis will use its proprietary, AI-enabled ionizable lipid discovery and optimization platform, AiLNP, to develop delivery technologies with the potential to improve targeting and biodistribution of LNP-based delivery. Lilly will contribute its expertise in drug discovery, development, and commercialization to support the advancement of the collaboration jointly discovered and developed by both companies.

GSK. GSK partnered with Hengrui Pharma (Lianyungang and Shanghai, China) to develop up to 12 medicines across several therapeutic areas (respiratory, immunology & inflammation, and oncology) in a deal worth up to $12.5-billion ($500 million upfront and $12 billion in milestone payments). A key drug candidate in the deal is HRS-9821, a PDE3/4 inhibitor in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, irrespective of background therapy.

The addition of HRS-9821 supports GSK’s goal to treat patients across the spectrum of COPD by including those who face continued dyspnea (shortness of breath) or who are unlikely to receive inhaled corticosteroids or biologics, based on their disease profile. HRS-9821 has demonstrated PDE3 and PDE4 inhibition, leading to increased bronchodilation and anti-inflammatory effects in early clinical and preclinical studies, according to information from GSK. In addition, HRS-9821 holds the opportunity to be delivered in a dry-powder inhaler formulation that strategically fits GSK’s inhaled respiratory portfolio.

GSK also inked a deal with Hutchmed (Hong Kong) for an exclusive development and license agreement, granting a GSK subsidiary worldwide rights, excluding Mainland China, Hong Kong, Macau and Taiwan, to develop and commercialize HMPL-A830, an antibody-targeted therapy conjugate (ATTC) focused on colorectal, pancreatic and lung cancer, in a deal worth up to $1.3 billion ($110 million upfront and $1.185 billion in milestone payments). HMPL-A830 will have its clinical development initially focused on colorectal, pancreatic, and lung cancer indications. The drug comprises a highly selective and potent Kirsten rat sarcoma (KRAS) small-molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor antibody.

Merck. Merck & Co./MSD and SciBrunch Therapeutics (Shanghai) entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral oncology drug, in a deal worth up to $2.1 billion ($400 million upfront and $1.7 billion in milestone payments). SPR2015 is a selective investigational preclinical molecular glue KRAS G12D (ON) inhibitor that has shown nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines while maintaining good selectivity over KRAS wildtype cells, according to information from Merck. KRAS G12D is the most common oncogenic RAS mutation in human tumors. This change leaves KRAS active and continuously signaling for cell proliferation and survival. In addition, SPR2015 has demonstrated antitumor efficacy as a monotherapy across multiple in vivo cell-derived and patient-derived xenograft models, according to the company.

Novartis. Novartis entered into a licensing and option agreement with Abogen Biosciences (Suzhou, China) to advance RNA-encoded therapeutics, in a deal worth up to $7.8 billion ($575 million upfront and $7.2 billion in potential milestone payments). The agreement includes an exclusive worldwide license to Abogen’s lead asset, ABO2203, as well as options to exclusively license other potential programs using Abogen’s proprietary RNA platform. ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager for treating certain autoimmune diseases. It is designed to reset B cells by using mRNA to direct the endogenous production of T-cell engagers in vivo. This approach offers a differentiated mechanism for B-cell depletion, potentially providing advantages over traditional recombinant T-cell engagers.

Novo. Novo entered into a license agreement with Hengrui Pharma (Shanghai) for HRS-1596, an obesity drug with potential for once-weekly oral dosing, in a deal worth up to $2.6 billion ($300 million upfront and $2.3 billion in milestone payments). The drug candidate is a Phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist. HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, Type 2 diabetes, and other metabolic diseases.

Pfizer. Pfizer inked a $10.5-billion deal ($650 million upfront payment and $9.85 billion in milestone payments) with Innovent Biologics (Suzhou, China) which includes licensing, co-development, and co-commercialization opportunities across a portfolio of antibody drug conjugates (ADCs) with differentiated payloads and multi-specific antibodies, consisting of 12 programs—eight Innovent-originated early-stage programs and four Pfizer-proposed discovery programs.

Regeneron. Regeneron Pharmaceuticals, a Tarrytown, New York-based bio/pharmaceutical company, formed an agreement with Hansoh Pharmaceuticals (Hong Kong) to acquire exclusive clinical development and commercial rights outside of the Mainland China, Hong Kong and Macau for a GLP-1/GIP receptor agonist, in a deal worth up to $2.01 billion ($80 million upfront and $1.93 billion in milestone payments). The therapeutic candidate (HS-20094) is in a Phase III trial in obesity in China and a Phase IIb study in diabetes.  

Roche. Roche and Hansoh Pharmaceutical (Shanghai) formed a strategic collaboration and license agreement for ADCs worth up to $15.5 billion ($400 million upfront, $110-million first-year anniversary payment, and $15 billion in milestone payments). The collaboration spans a portfolio of ADC programs, comprising two preclinical Hansoh ADC programs and multiple ADC programs based on Roche-proposed targets using Hansoh’s proprietary ADC technology platform. Under the agreement, Hansoh will lead the early development of the programs up to the completion of global Phase Ia clinical trials. Roche will be responsible for further developing the programs worldwide (excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan). Hansoh will retain all rights to develop, register and commercialize the programs within the Chinese Mainland, Hong Kong, Macau, and Taiwan.

Roche also formed a smaller pact with Simcere Zaiming (Nanjing, China) for an exclusive global licensing agreement for the development and commercialization of Simcere’s SIM0660, a tri-specific antibody with therapeutic potential across B-cell-mediated diseases, in a deal worth up to $1.5 billion ($75 million upfront and $1.5 billion in milestone payments). SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens, CD79a and CD19, to induce potent T cell-mediated cytotoxicity while limiting cytokine release. With its dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide broad coverage across B-cell mediated diseases and may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies. In addition, SIM0660 also has therapeutic potential for B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit, according to information from the company.

In addition, Roche partnered with Rona Therapeutics (Shanghai, China), which specializes in RNAi therapeutics, under which Roche has been granted an exclusive worldwide license for Rona’s investigational RNAi candidate for obesity and metabolic diseases, in a deal worth up to $1.16 billion ($100 million upfront and $1.06 billion in potential milestone payments). The RNAi candidate targets activin receptor-like kinase 7 (ALK7), a target for obesity and metabolic diseases using the company’s proprietary extrahepatic delivery platform. ALK7, encoded by the ACVR1C gene, is predominantly expressed in adipose tissue. ALK7 inhibition acts directly on adipose tissue biology. This mechanism creates the potential for ALK7-targeted therapies to be used independently or in combination with established obesity treatments, such as incretins.

Sanofi. In March (March 2026), Sanofi inked an exclusive license with Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical (Hong Kong) that grants Sanofi an exclusive license to develop, manufacture, and commercialize rovadicitinib, a small-molecule drug for treating certain blood cancers, in a $1.53-billion deal ($135 million upfront and $1.395 billion in milestone payments). Rovadicitnib was approved for marketing by China’s National Medical Products Administration in February (February 2026) for the first-line treatment of adult patients with certain blood cancers: intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. The drug is also under clinical development for treating chronic graft-versus-host disease. In China, it has advanced to Phase III trials, and in the US, it has been approved for Phase II clinical studies. 

Recent Feature Articles

Navigating FDA: Mfg, Inspections & Supply Chain

By
Change has been the operative word at FDA not only in leadership but in new policy initiatives impacting manufacturing, the inspection process, and the supply chain. An upcoming DCAT webinar sums up the latest.

Incentivizing US-Based Contract Biomanufacturing 

By
The Biotechnology Innovation Organization (BIO) is recommending a seven-point action plan to increase US competitiveness in biotech, including incentives for increasing US-based contract biomanufacturing.

The Next Round in the Obesity Drug Market 

By
Pfizer’s move to secure $1.5 billion in funding from the investment firm, Blackstone, to advance its late-stage GLP-1 candidate is heating up the obesity drug market. A look at the revenue leaders and contenders.

CDMO Moves: Lonza Increasing Position in US

By
Lonza is increasing its position in the US with a pending acquisition of five CDMO sites from the life-sciences business of Merck KGaA. What sites and capabilities is the company gaining in the deal?